$1.57
-0.02(-1.26%)
Mkt Cap $10M
$1.44
$5.68
52-Week Range
At a Glance
AI-generatedChemomab Therapeutics Ltd.
6-K
Chemomab Therapeutics Ltd. announced financial results for the full year and fourth quarter ended December 31, 2025, with net loss of $9.0 million for the year and cash position of $10.4 million providing runway through end of Q1 2027. The company highlighted successful FDA End-of-Phase 2 meeting alignment on a single Phase 3 trial pathway for nebokitug in PSC.$10M
Market Cap
—
Revenue
-$7M
Net Income
Employees20
Fundamentals
How The Business Makes Money
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001534248
ISINUS16385C2035
CUSIP16385C203
Phone972 77 331 0156
AddressBuilding 7, Tel Aviv, 6158002, IL
SEC EDGAR